You are here

Results and implications of CAROLINA (CARdiOvascular Safety of LINAgliptin) comparing linagliptin vs glimepiride

Thursday, 19 September 2019, 13:15 - 14:15, Joslin Hall

Chair: J. Rosenstock, US

J. Rosenstock, US: Introduction and study background

M.A. Espeland, US:  Study design and baseline characteristics

S.E. Kahn, US: Metabolic and weight outcomes

N. Marx, DE: Cardiovascular, mortality and hospitalisation outcomes

B. Zinman, US: Safety and comprehensive hypoglycaemia analyses

D.K. McGuire, US: Clinical implications

P.D. Home, UK: Comentary